logo-loader
viewANGLE PLC

Something for everyone at next Wednesday's Proactive Investors One2One Forum in London: ANGLE, Deltex Medical, Silence Therapeutics and Stanley Gibbons

We have a line-up that offers something for everyone at the Proactive Investors One2One Forum in London next Wednesday 23rd November. ANGLE, whose star really is in the ascendancy, will be joined by Deltex Medical, Silence Therapeutics and Stanley Gibbons

speech_350_4ec517366fadc.jpg

Exciting barely covers it. We have a line-up that offers something for everyone at the Proactive Investors One2One Forum in London next Wednesday 23rd November. ANGLE, whose star really is in the ascendancy, will be joined by Deltex Medical, Silence Therapeutics and Stanley Gibbons.

Each has attracted an incredible amount of interest. So if you haven’t signed up already, you really need to do so soon to avoid disappointment. Please click here to register for the event.


The recent noise around intellectual property group ANGLE (LON:AGL) has been incredible and has followed the success of a breakthrough cancer screening device developed by its Parsortix business.

The longest established of London’s quoted IP companies, there is more to ANGLE than this one business. So this is a stock that will appeal to those following IP Group (LON:IPO) and Fusion IP (LON:FIP).

Meanwhile, Parsortix will appeal to those investors interested in medical technology, so this is companies such as Avacta (LON:AVCT) and Sphere Medical (LON:SPHR).

Meanwhile, ANGLE’s Novocellus business will be of interest to those people following cutting edge healthcare firms such as Axis-Shield (LON:ASD).

In Geomerics the group has an investment at the very cutting edge of video game technology whose Enlighten middleware is included in titles such as Battlefield 3.

So ANGLE is three separate investments in one.

That said the real driver of the share price has been the development of Parsortix and its blood monitor that picks up the early signs of cancer.

The recent spate of positive announcements charting the device’s development has driven up ANGLE’s value by 200 per cent.

Although still in its infancy, Parsortix technology may ultimately have the ability to identify all the hard tumour types, without knowing in advance which cancer is expected. 

This is a step on from the existing means of identifying circulating cancer cells, where the tests are specific to each cancer type and even then are not totally reliable. 

“We think ours has a much more universal application - hopefully to all solid tumours,” chief executive Andrew Newland said recently.

Followers of LidCo (LON:LID) will probably already have half an eye on Deltex Medical (LON:DEMG), which is aiming to get its revolutionary CardioQ-ODM blood monitoring system accepted by health services and hospitals around the world.

Recent updates from the company reveal it is making good headway in achieving this aim in the UK.

CardioQ-ODM (Oesophageal Doppler Monitor) is a blood monitoring system that requires a new disposable probe every time the system is used on a new patient, meaning that Deltex gets a consumables-driven revenue stream as well as income from sales of the device itself.

After selecting CardioQ as one of the first products for review by its newly-established Medical Technologies Advisory Committee, the device received the backing of the UK’s health spending watchdog NICE.

NICE estimates that its recommendation applies to 837,000 surgical patients each year in the NHS in England alone.

It is estimated the device could save the NHS £1 billion a year. Yet the potential of CardioQ is only just being recognised by healthcare providers and the market.

Turning from healthcare to biotechnology, and specifically Silence Therapeutics (LON:SLN), our recent article describes the group as leaner and fitter than it ever has been.

And more to the point it is fully funded to develop a potentially breakthrough treatment for cancer.

The latest update on its phase I clinical trials, released earlier this month, made encouraging reading.

This is a stock that will appeal to fans of Sareum Holdings (LON:SAR) and ValiRx (LON:VAL), who understand early-stage biotech investment.

Finally, if alternative investment is your bag then you are no doubt following two quoted companies at the cutting edge of this specialist area.

One would be Noble Investments (LON:NBL), which specialises in coins, and the other is undoubtedly Stanley Gibbons, whose shop on the Strand is a Mecca for stamp collectors.

The recent opening of an office in Hong Kong reveals Stanley Gibbons going international.

China is a real hotspot for philately and a potentially huge market for a company whose name resonates worldwide.

Bringing us up to speed on the group’s expansion plans and the success of its investment products will be chief executive Michael Hall.

Quick facts: ANGLE PLC

Price: 61 GBX

AIM:AGL
Market: AIM
Market Cap: £105.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ANGLE PLC submits its flagship Parsortix liquid biopsy diagnostic to the FDA

ANGLE PLC (LON:AGL) (OTCQX:ANPCY) CEO Andrew Newland tells Proactive the company has submitted its patent-protected, flagship Parsortix liquid biopsy diagnostic for clearance to the FDA.  Newland says this is a tremendous opportunity for ANGLE, as he says ANGLE is the first company to...

on 30/10/19

5 min read